Campylobacter spp Bloodstream Infections in Immunocompetent vs Immunodeficient Patients: A Multinational Cohort Study (2009-2024).

Authors

María Paniagua-García, José Manuel Bernal-Aznar, Effrossyni Gkrania-Klotsas, Isobel Soper, María Lluisa Pedro-Botet Montoya, Esteban A Reynaga, Adoración Valiente, María Carmen Domínguez-Jiménez, Andrea Lombardi, María Navarro, Fernando Cobo, Maristela Freire, Ana V Halperin, Laia Alsina, Marguax Garzaro, Silvia Castro Caruso Christ, Julia Laporte-Amargos, Enrique Ruiz de Gopegui-Bordes, Luis Martínez-Martínez, Maura S Oliveira, Victoria García-López, Francisco J Martinez-Marcos, Emilio Cendejas, Alfonso Del Arco-Jiménez, Mónica Chávez-Caballero, Salvador López-Cardenas, Manuel Antonio Rodríguez-Iglesias, Carla A Alonso, Maddalena Giannella, Adelina Gimeno-Gascón, Pilar Sánchez-Suero, Silvia Jiménez-Jorge, Jerónimo Pachón, María E Pachón-Ibáñez, Elisa Cordero, Campybact Working Group and The ESCMID ESGICH, Campybact Working Group and The ESCMID ESGICH

Published in

Open forum infectious diseases. Volume 13. Issue 7. Pages ofag380. Epub Jun 23, 2026.

Abstract

Campylobacter spp bloodstream infections (BSIs) are an emerging clinical challenge, yet information on their clinical features remains limited. We aimed to evaluate their differential clinical characteristics and outcomes in immunocompetent (IC) and immunodeficient (ID) patients.
A multicenter, multinational, retrospective cohort study of consecutive Campylobacter spp BSIs between 2009 and 2024 was carried out. Demographics, Charlson comorbidity index, types of immunodeficiencies, clinical characteristics, and antimicrobial susceptibility were analyzed. The primary outcomes were relapse or reinfection and death (all-cause mortality outcome).
A total of 261 episodes were included, 89 (34.1%) in IC and 172 (65.9%) in ID patients. Among the 172 ID patients, 104 (60.5%) and 68 (39.5%) had humoral or nonhumoral immunodeficiency (primary or secondary), and 42 (24.4%) had primary immunodeficiencies (PIDs). Patients with humoral immunodeficiency (humoral-ID patients) were younger (median age, 40 years [interquartile range, 23-66 years]), had lower Charlson comorbidity indexes (2 [1-5]), and had a higher frequency of previous Campylobacter spp infection. Resistance rates to fluoroquinolones (75%) and macrolides (14.5%) were high. BSI relapse or reinfection occurred in 21 (8.0%) patients, mostly humoral-ID patients (n = 19 [18.3%]), 11 (57.9%) of whom had PID. Death occurred with 30 days (all-cause mortality outcome) in 26 patients (9.9%) across the entire cohort; the 30-day mortality rate was lower in humoral-ID (n = 5 [4.8%]) than in IC (n = 12 [13.5%]; P = .05) patients.
Humoral-ID patients and those with Campylobacter spp BSI were younger and had fewer comorbid conditions, and Campylobacter coli was the most frequent species. Relapse or reinfection was common in humoral-ID patients, particularly those with PID. The antimicrobial resistance in C coli and Campylobacter jejuni represents a clinical concern.

PMID:
42488720
Bibliographic data and abstract were imported from PubMed on 23 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.